We identified four core genes (CTSB, HNRNPL,KRAS and MAP1LC3A) and constructed potential regulatory network, which may providethe potential therapeutic targets for ICAS and pave the way for furtherresearch. Here, MAP1LC3A is linked to familial isolated congenital asplenia.